Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical device developer NuVasive
So what: A San Diego jury awarded Medtronic
Now what: For a company the size of NuVasive, a $101 million judgment is no small matter. However, the company had more than $500 million in cash and equivalents on its balance sheet as of June 30. The bigger question for the company will be what this means for the future, as it will either have to either stop selling the infringing product or pay Medtronic for use of the technology. NuVasive has said that it will challenge the decision, but investors might want to consider what the future looks like if the current verdict holds.
Want to keep up to date on these stocks?
The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer owns shares of Medtronic, but does not have a financial interest in any of the other companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.